| Zacks Company Profile for Voyager Therapeutics, Inc. (VYGR : NSDQ) |
|
|
| |
| • Company Description |
| Voyager Therapeutics, Inc. is a gene therapy company. It focuses on the development of treatments for patients suffering from severe diseases of the central nervous system. Its pipeline includes VY-AADC01, which is in Phase 1b clinical trials for treatment of Parkinson's disease and preclinical programs comprise VY-SOD101 for a monogenic form of amyotrophic lateral sclerosis, VY-FXN01 for Friedreich ataxia and VY-HTT01 for Huntington's disease as well as VY-SMN101 for neuromuscular disease. Voyager Therapeutics, Inc. is headquartered in Cambridge, Massachusetts.
Number of Employees: 172 |
|
|
| |
| • Price / Volume Information |
| Yesterday's Closing Price: $3.55 |
Daily Weekly Monthly
 |
| 20 Day Moving Average: 623,817 shares |
| Shares Outstanding: 55.34 (millions) |
| Market Capitalization: $196.44 (millions) |
| Beta: 0.85 |
| 52 Week High: $9.55 |
| 52 Week Low: $2.65 |
| Short Interest Ratio: |
| |
% Price Change |
% Price Change Relative to S&P 500 |
| 4 Week |
-1.39% |
-5.08% |
| 12 Week |
12.34% |
-5.51% |
| Year To Date |
-37.39% |
-41.37% |
|
|
|
|
| |
|
|
| |
| • General Corporate Information |
Officers
Alfred Sandrock - Chief Executive Officer; President; and Director
Michael Higgins - Chairman
Nathan Jorgensen - Chief Financial Officer
Grace E. Colon - Director
James Geraghty - Director
|
|
Peer Information
Voyager Therapeutics, Inc. (CORR.)
Voyager Therapeutics, Inc. (RSPI)
Voyager Therapeutics, Inc. (CGXP)
Voyager Therapeutics, Inc. (BGEN)
Voyager Therapeutics, Inc. (GTBP)
Voyager Therapeutics, Inc. (RGRX)
|
|
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-BIOMED/GENE
Sector: Medical
CUSIP: 92915B106
SIC: 2836
|
|
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 03/01/25
Next Expected EPS Date: 08/05/25
|
|
Share - Related Items
Shares Outstanding: 55.34
Most Recent Split Date: (:1)
Beta: 0.85
Market Capitalization: $196.44 (millions)
|
|
|
|
|
| |
| • EPS Information |
• Dividend Information |
| Analyst Coverage: No |
Dividend Yield: 0.00% |
| Current Fiscal Quarter EPS Consensus Estimate: $-0.48 |
Indicated Annual Dividend: $0.00 |
| Current Fiscal Year EPS Consensus Estimate: $-1.99 |
Payout Ratio: |
| Number of Estimates in the Fiscal Year Consensus: 7.00 |
Change In Payout Ratio: |
| Estmated Long-Term EPS Growth Rate: % |
Last Dividend Paid: NA - $0.00 |
| Next EPS Report Date: 08/05/25 |
|
|
|
| |
